Back to Journals » OncoTargets and Therapy » Volume 13

RETRACTED ARTICLE: Identification of Osteosarcoma Metastasis-Associated Gene Biomarkers and Potentially Targeted Drugs Based on Bioinformatic and Experimental Analysis

Authors Cao MD, Song YC, Yang ZM, Wang DW, Lin YM, Lu HD

Received 7 April 2020

Accepted for publication 27 July 2020

Published 14 August 2020 Volume 2020:13 Pages 8095—8107

DOI https://doi.org/10.2147/OTT.S256617

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Prof. Dr. Nicola Silvestris



This paper has been retracted.

Cao MD, Song YC, Yang ZM, Wang DW, Lin YM, Lu HD. Onco Targets Ther. 2020;13:8095-8107.

We, the Editors and Publisher of OncoTargets and Therapy, have retracted the following article.

Concerns were raised about the integrity of the data in the article after it was found images from Figure 6 had been duplicated with those from other unrelated articles. Specifically,

  • The image for Figure 6D, MG63, WT, has been duplicated with the images for Figure 3A, SW620, miR-1236-3p mimics and Figure 2b, MDA-MB-231, Con, from Zhao Y, Zhou H, Shen J, et al. MiR1236-3p Inhibits the Proliferation, Invasion, and Migration of Colon Cancer Cells and Hinders Epithelial Mesenchymal Transition by Targeting DCLK3. Front Oncol. 2021;11:688882. https://doi.org/10.3389/fonc.2021.688882 and Wang S, Zhang Y, Ren T, et al. A novel 4-aminoquinazoline derivative, DHW-208, suppresses the growth of human breast cancer cells by targeting the PI3K/AKT/mTOR pathway. Cell Death Dis. 2020;11:491. https://doi.org/10.1038/s41419-020-2690-y, respectively.
  • The image for Figure 6D, MG63, shTLR7, has been duplicated with the image for Figure 3A, SW620, Mimics control, from Zhao Y, et al. Front Oncol. 2021;11:688882.
  • The image for Figure 6E, MG63, WT, has been duplicated with the image for Figure 2b, MDA-MB-231, 400 and Figure 6E, Si-SLC26A4-AS1, from Wang S, et al, Cell Death Dis. 2020;11:491 and Li Z, Lin W, Zheng J, et al. Identification of immune-related lncRNAs to improve the prognosis prediction for patients with papillary thyroid cancer. Biosci Rep. 2021;41(2): BSR20204086. doi: https://doi.org/10.1042/BSR20204086, respectively.
  • The image for Figure 6E, MG63, shTLR7, has been duplicated with the images for Figure 3B, SW620, miR-1236-3p mimics; Figure 2b, MDA-MB-231, 200; Figure 6E, NC; Figure 10H, scCD200R1 and Figure 2E, sh-KIF4A, from Zhao Y, et al. Front Oncol. 2021;11:688882; Wang S, et al. Cell Death Dis. 2020;11:491; Li Z, et al. Biosci Rep. 2021;26:41(2):BSR20204086; Ling B, Ye G, Zhao Q, Jiang Y, Liang L, Tang Q. Identification of an Immunologic Signature of Lung Adenocarcinomas Based on Genome-Wide Immune Expression Profiles. Front Mol Biosci. 2021;7:603701: https://doi.org/10.3389/fmolb.2020.603701 and Feng S, Luo S, Ji C, et al. miR-29c-3p regulates proliferation and migration in ovarian cancer by targeting KIF4A. World J Surg Onc. 2020;18:315. https://doi.org/10.1186/s12957-020-02088-z, respectively.

When approached for an explanation, the authors were cooperative and provided some data for their study. However, the author’s explanation and the provided data did not satisfactorily explain how the duplication of these images occurred and was unable to alleviate the journal’s concerns regarding the validity of the findings. As verifying the validity of published work is core to the integrity of the scholarly record, we are therefore retracting the article and the authors were notified of this.

We have been informed in our decision-making by our editorial policies and COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as ‘Retracted’.

Creative Commons License © 2020 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.